1Durak I, Durak H, Erign M, et al. Somatostatin receptors in the orbits[J]. Clin Nucl Med, 1995,20:237-242.
2Ozata M, Bolu E, Sengul A, et al. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sI- CAM-1 levels[J] .Thyroid,1996,6:283-288.
3Krassas G E, Dumas A, Pontikides N, et al. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease [J]. Clin Endocrinol, 1995,42: 571-580.
4Kung A W C, Michon J, Tai K S, et al. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy [J]. Thyroid, 1996,6: 318-324.
5Krassas G E, Kaltsas T, Dumas A, et al. Lanreotide in the treatment of patients with thyroid eye disease[J]. Eur J Endocrinol, 1997,136: 416-422.
6Krassas G E, Doumas A, Kaltsas T, et al. Somatostatin receptors scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease [J].Thyroid, 1999,9: 47-52.
7Uysal A R, Corapcioglu D, Tonyukuk V C, et al. Effects of octreotide treatment on Graves' ophthalmopathy [J]. Endocrinol J, 1999,46: 573-577.
8Heufelder A E. Somatostatin analogues in Graves' ophthalmopathy[J] .J Endocrinol Invest, 1997,20 (suppl to no 7):50-52.
9Krassas G E. Somatostatin analogues in the treatment of thyroid eye disease [J]. Thyroid, 1998,8: 443-445.
10Pasquali D, Vassallo P, Esposito D, et al. Somatostatin receptors gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy[J]. J Mol Endocrinol, 2000,25: 63-71.
